Myelodysplastic Syndromes
The MDS Sessions: highlights from ASH 2020
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 27th April 2021
The Post-EBMT VJSessions from VJHemOnc
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…
Date: 7th April 2021
Post-EBMT highlights in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be…
Date: 6th April 2021
The MDS Sessions: Giants in MDS
The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the…
Date: 17th March 2021
Updates for the management of MDS from ASH 2020
During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the…
Date: 16th February 2021
The MDS Sessions: treating MDS around the world
The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS…
Date: 12th February 2021
The MDS sessions: lower-risk disease
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…
Date: 7th December 2020
The MDS sessions: clinical trial participation, endpoints & approvals
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…
Date: 17th November 2020
The AML Sessions: IDH inhibitors
IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown…
Date: 3rd November 2020
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…
Date: 28th July 2020
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment…
Date: 16th July 2020
Systemic mastocytosis: current landscape, novel agents and COVID-19
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…
Date: 2nd June 2020
